Ziftomenib + venetoclax/azacitidine (ven/aza) or cytarabine/daunorubicin (7+3)

May 12, 2026 — Kura Oncology, Inc. (Nasdaq: KURA) reported first quarter 2026 financial results and provided updates on its commercial and clinical programs. In the first full quarter of commercialization, KOMZIFTI (ziftomenib), an oral menin inhibitor for relapsed/refractory NPM1-mutated acute myeloid leukemia (AML), generated $5.8 million net product revenue, with 85 new patient starts and 157 total prescriptions. The company reported >93% payer coverage with favorable positioning across plans covering >12 million lives, citing early launch dynamics such as repeat use, switching, and combination adoption.

Kura highlighted ongoing enrollment in multiple ziftomenib AML trials (including KOMET-017 Phase 3 frontline, and combination studies KOMET-008 and KOMET-007) and announced first patient dosed in a Japanese Phase 2 registrational trial for R/R NPM1-mutant AML. In solid tumors, Kura presented darlifarnib + cabozantinib data in clear cell RCC showing 44% ORR, 94% DCR, and 75% tumor shrinkage.

Financially, Kura reported net loss of $73.3M (vs. $57.4M Q1 2025), R&D $65.3M, SG&A $31.6M, and $580.8M in cash/investments; it expects this plus $180M anticipated Kyowa Kirin collaboration payments to fund the ziftomenib AML program through first KOMET-017 Phase 3 topline results (anticipated 2028).